The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
The deal, expected to be announced Monday, will result in Pfizer shareholders owning most of the new company, with Mylan's shareholders owning slightly more than 40%, said the person, who declined to be named because the plans aren't yet public. The Wall Street Journal first reported the news.
The combined company, which will sell Mylan's EpiPen and Pfizer's Viagra, will receive a new name and be domiciled in the U.S. The deal will be structured in what's known as a reverse Morris trust, with Pfizer's Upjohn business divested and then combined with Mylan.
The combined company could draw annual sales of more than $20 billion. Mylan reported 2018 sales of $11.4 billion and while Pfizer hasn't broken out full-year numbers for its China-based Upjohn unit, its first quarter sales were just more than $3 billion. Pfizer's total 2018 revenue was $53.6 billion.
Mylan's stock is down 76% from its 2015 high amid scrutiny of its price increases on the EpiPen, pressure on U.S. generic drug prices and an investigation into drug-price collusion in the industry. The deal is the "best-case outcome" for Mylan, said Jared Holz, health-care strategist at Jefferies. Mylan said last year it had formed a strategic review committee to evaluate options for the future of the company.
Pfizer investors are more mixed on the deal, according to Holz, who said he's received feedback from shareholders since the Journal's first report Saturday morning.
It would mark a further move under new Chief Executive Albert Bourla to streamline Pfizer's focus on branded medicines and vaccines. The company agreed in December to combine its consumer-health business, which sells Advil among other brands, with GlaxoSmithKline's in a joint venture of which GSK has a majority controlling interest. In June, Pfizer said it would spend $11.4 billion to acquire the cancer-drug maker Array BioPharma.
The Mylan deal, Holz said, could be "dilutive to earnings over the near term because of how profitable Upjohn is to Pfizer."
The new company will be helmed by Pfizer's Michael Goettler, currently president of the Upjohn business. Mylan Chairman Robert Coury will be executive chairman, and Mylan CEO Heather Bresch will depart.
Holz called the management shuffle a positive for the deal, noting Mylan's had "one of the most out-of-favor management teams in all of health care."